Coagulopathy during COVID-19 infection: a brief review

The COVID-19 pandemic caused by SARS-CoV-2 continues to spread rapidly due to its virulence and ability to be transmitted by asymptomatic infected persons. If they are present, the symptoms of COVID-19 may include rhinorrhea (runny nose), headache, cough, and fever. Up to 5% of affected persons may...

Full description

Saved in:
Bibliographic Details
Published in:Clinical and experimental medicine 2023-07, Vol.23 (3), p.655-666
Main Authors: Cunningham, Robin M., Johnson Moore, Kyle L., Moore, Jacen S.
Format: Article
Language:English
Subjects:
Angiopoietin
Cough
COVID-19
Cytology
Disease transmission
Disseminated intravascular coagulation
Erythrocytes
Fibrinogen
Hematology
Interleukin 6
Internal Medicine
Laboratories
Mechanical ventilation
Medicine
Medicine & Public Health
Oncology
Peripheral blood
Prothrombin
Respiratory distress syndrome
Respiratory failure
Review
Review Article
Serum levels
Severe acute respiratory syndrome coronavirus 2
Thromboplastin
Virulence
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:The COVID-19 pandemic caused by SARS-CoV-2 continues to spread rapidly due to its virulence and ability to be transmitted by asymptomatic infected persons. If they are present, the symptoms of COVID-19 may include rhinorrhea (runny nose), headache, cough, and fever. Up to 5% of affected persons may experience more severe COVID-19 illness, including severe coagulopathy, acute respiratory distress syndrome (ARDS) characterized by respiratory failure that requires supplementary oxygen and mechanical ventilation, and multi-organ failure. Interestingly, clinical evidence has highlighted the distinction between COVID-19-associated coagulopathy (CAC) and disseminated intravascular coagulation (DIC). Patients with CAC exhibit different laboratory values than DIC patients for activated partial thromboplastin time (aPTT) and prothrombin time (PT) which may be normal or shortened, varying platelet counts, altered red blood cell morphology, unique bleeding complications, a lack of schistocytes in the peripheral blood, and no decrease in fibrinogen levels. In this review, we consider the search for 1) laboratory results that can diagnose or predict development of CAC, including serum levels of D-dimers, fibrinogen, interleukin-6 (IL-6) and the growth factor angiopoietin-2 (Ang-2), 2) mechanisms of CAC induction, and 3) novel therapeutic regimens that will successfully treat COVID-19 before development of CAC.
ISSN:1591-9528
1591-8890
1591-9528
DOI:10.1007/s10238-022-00891-4